A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML
- PMID: 19144992
- DOI: 10.1182/blood-2007-11-126664
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML
Abstract
Currently, FLT3 tyrosine kinase inhibitors (TKIs) are emerging as the most promising drug therapy to overcome the dismal prognosis of acute myelogenous leukemia (AML) patients harboring internal tandem duplications (ITDs) of FLT3. However, up-front drug resistance occurs in approximately 30% of patients, and molecular mechanisms of resistance are poorly understood. Here, we have uncovered a novel mechanism of primary resistance to FLT3 TKIs in AML: an FLT3 receptor harboring a nonjuxtamembrane ITD atypically integrating into the beta-2 sheet of the first kinase domain (FLT3_ITD627E) induces dramatic up-regulation of the anti-apoptotic myeloid cell leukemia 1 protein (MCL-1). Using RNA interference technology, deregulated MCL-1 protein expression was shown to play a major role in conferring the resistance phenotype of 32D_ITD627E cells. Enhanced and sustained binding of the adaptor protein GRB-2 to the FLT3_ITD627E receptor is involved in MCL-1 up-regulation and is independent from TKI (PKC412)-induced inhibition of the receptor kinase. Thus, we describe a new mechanism of primary resistance to TKIs, which operates by reprogramming local and distant signal transduction events of the FLT3 tyrosine kinase. The data presented suggest that particular ITDs of FLT3 may be associated with rewired signaling and differential responsiveness to TKIs.
Comment in
-
Fathoming flt3.Blood. 2009 Apr 23;113(17):3889-90. doi: 10.1182/blood-2009-02-205435. Blood. 2009. PMID: 19389891 No abstract available.
Similar articles
-
Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.Ann Hematol. 2010 Jul;89(7):653-62. doi: 10.1007/s00277-009-0889-1. Epub 2010 Jan 30. Ann Hematol. 2010. PMID: 20119833
-
CCL5 mediates _target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.Mol Oncol. 2020 Apr;14(4):779-794. doi: 10.1002/1878-0261.12640. Epub 2020 Feb 13. Mol Oncol. 2020. PMID: 31955503 Free PMC article.
-
Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells.PLoS One. 2011;6(9):e25351. doi: 10.1371/journal.pone.0025351. Epub 2011 Sep 28. PLoS One. 2011. PMID: 21980431 Free PMC article.
-
The Future of _targeting FLT3 Activation in AML.Curr Hematol Malig Rep. 2017 Jun;12(3):153-167. doi: 10.1007/s11899-017-0381-2. Curr Hematol Malig Rep. 2017. PMID: 28421420 Review.
-
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.Expert Rev Hematol. 2017 Dec;10(12):1033-1045. doi: 10.1080/17474086.2017.1397510. Epub 2017 Oct 30. Expert Rev Hematol. 2017. PMID: 29069942 Review.
Cited by
-
FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.Leuk Lymphoma. 2014 Feb;55(2):243-55. doi: 10.3109/10428194.2013.800198. Epub 2013 Jun 5. Leuk Lymphoma. 2014. PMID: 23631653 Free PMC article. Review.
-
Tyrosine kinase inhibitors _targeting FLT3 in the treatment of acute myeloid leukemia.Stem Cell Investig. 2017 Jun 2;4:48. doi: 10.21037/sci.2017.05.04. eCollection 2017. Stem Cell Investig. 2017. PMID: 28607922 Free PMC article. Review.
-
Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.Leukemia. 2018 Feb;32(2):313-322. doi: 10.1038/leu.2017.257. Epub 2017 Aug 14. Leukemia. 2018. PMID: 28895560 Free PMC article.
-
Mechanisms of resistance to _targeted therapies for relapsed or refractory acute myeloid leukemia.Exp Hematol. 2022 Jul;111:13-24. doi: 10.1016/j.exphem.2022.04.001. Epub 2022 Apr 10. Exp Hematol. 2022. PMID: 35417742 Free PMC article. Review.
-
Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?Curr Opin Hematol. 2014 Mar;21(2):72-8. doi: 10.1097/MOH.0000000000000022. Curr Opin Hematol. 2014. PMID: 24468836 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous